ERBB2 and neoplasm: Hopefully the results of this trial will provide more evidence on defining the threshold levels /lower limits of HER2 expression required to benefit from an ADC therapeutic approach, such as T-Dxd, and determining the clinical significance of distinguishing HER2-low BC from HER2-0 tumor by using current testing methods.